Senior Director, Search & Evaluation Late TA Lead, Immunology

Main Responsibilities & Accountabilities

• Serve as the senior S&E leader within the TALT, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.
• Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.
• Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas.
• NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations.
• Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.
• Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.
• Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.
• Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution.
• Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.

Qualifications & Experience Requirements

• 15+ years in biopharma with significant experience in clinical development, external innovation, or business development.
• Advanced degree required (MD, PhD, or equivalent).
• Deep clinical expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.
• Promised track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.
• Strong understanding of regulatory pathways, market access, and competitive standards of care.